BI 2536
Term · Oncology and biomedicine · MLC-T-ONC-001021
A substance being studied in the treatment of cancer. It prevents cells from dividing and may block the growth of some tumors. It is a type of mitotic inhibitor.
A small molecule compound with potential antineoplastic activities. BI 2536 binds to and inhibits Polo-like kinase 1 (Plk1), resulting in mitotic arrest, disruption of cytokinesis, and apoptosis in susceptible tumor cell populations. Plk1, a serine/threonine-protein kinase, is a key regulator of multiple processes fundamental to mitosis and cell division.
| Identifier | MLC-T-ONC-001021 |
|---|---|
| Field | Oncology and biomedicine |
| References | NCI Dictionary of Cancer Terms; National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-001021",
"term": "BI 2536",
"field": "Oncology and biomedicine",
"definitions": [
"A substance being studied in the treatment of cancer. It prevents cells from dividing and may block the growth of some tumors. It is a type of mitotic inhibitor.",
"A small molecule compound with potential antineoplastic activities. BI 2536 binds to and inhibits Polo-like kinase 1 (Plk1), resulting in mitotic arrest, disruption of cytokinesis, and apoptosis in susceptible tumor cell populations. Plk1, a serine/threonine-protein kinase, is a key regulator of multiple processes fundamental to mitosis and cell division."
],
"references": [
"NCI Dictionary of Cancer Terms",
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/bi-2536/"
}
Record 3,516 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.